Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 2776-2786, 2023.
Artículo
en Inglés
| WPRIM
| ID: wpr-1007602
ABSTRACT
Epidermal growth factor receptor ( EGFR ) mutations are common oncogenic driver mutations in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine kinase inhibitors (TKIs) is beneficial for patients with advanced and early-stage NSCLC. With the development of next-generation sequencing technology, numerous patients have been found to have more than one genetic mutation in addition to a single EGFR mutation; however, the efficacy of conventional EGFR-TKIs and the optimal treatments for such patients remain largely unknown. Thus, we review the incidence, prognosis, and current treatment regimens of EGFR compound mutations and EGFR concomitant mutations to provide treatment recommendations and guidance for patients with these mutations.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de Proteínas Quinasas
/
Receptores ErbB
/
Neoplasias Pulmonares
/
Mutación
Límite:
Humanos
Idioma:
Inglés
Revista:
Chinese Medical Journal
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS